.September 17, 2024 at 5:00:09 PM

Citigroup upgraded Sanofi (NASDAQ:SNY) to Buy from Hold, raising the price target to EUR 130 from EUR 125. Sanofi, in partnership with Regeneron Pharmaceuticals, secured FDA approval for an expanded label for Dupixent, broadening its patient base. Despite short-term volatility, Sanofi’s stock shows resilience, with a market capitalization of approximately $142.67 billion and active investor interest. The FDA approval for Dupixent and Citigroup’s upgraded rating position Sanofi for future growth, reflecting the company’s commitment to addressing medical needs and expanding its product portfolio.